Results 271 to 280 of about 31,072 (344)

Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis

open access: yesEuropean Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo   +3 more
wiley   +1 more source

Computed tomography of the equine temporohyoid joint: Association between imaging changes and potential risk factors

open access: yesEquine Veterinary Journal, Volume 58, Issue 1, Page 125-133, January 2026.
Abstract Background Temporohyoid osteoarthropathy (THO) is characterised by bone proliferation and cartilage ossification caused by infectious and degenerative conditions, amongst others. Objectives To describe the variable appearance of the temporohyoid joint (THJ) on computed tomography (CT) and investigate associations between CT changes and ...
Rupert F. Dash   +3 more
wiley   +1 more source

Meningeal lymphatics as a therapeutic target for neurodegenerative disorders. [PDF]

open access: yesTransl Neurodegener
Feng Y   +6 more
europepmc   +1 more source

Patients with chronic post‐dural puncture headache do not have typical imaging features of intracranial hypotension: An MRI study using the Bern score

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 193-201, January 2026.
Abstract Objective This study evaluated cranial magnetic resonance imaging (MRI) signs in patients with post‐dural puncture headache (PDPH) using an established assessment score developed for spontaneous intracranial hypotension (Bern score). We hypothesize that patients with chronic PDPH do not have typical imaging features of intracranial hypotension.
Charlotte Zander   +9 more
wiley   +1 more source

Can atogepant be a preventive treatment for cluster headache?—Insights from a case series

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 336-340, January 2026.
Abstract Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an
Catarina Serrão   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy